Endoscopic Stenting Techniques for Gastric Outlet Obstruction
Trial Summary
What is the purpose of this trial?
This trial compares two less invasive treatments for patients with a blocked stomach due to cancer. One method uses ultrasound to create a new pathway between the stomach and small intestine, while the other uses a stent to keep the blocked area open. The goal is to see which method is safer and more effective.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment for gastric outlet obstruction?
Research shows that self-expandable metal stents (SEMS) and lumen-apposing metal stents (LAMS) are effective in relieving symptoms of gastric outlet obstruction, especially when caused by cancer. These stents help open up blocked areas, allowing food to pass through more easily, and have shown high technical success in studies.12345
Is the use of lumen-apposing metal stents (LAMS) generally safe for humans?
How is the treatment with Lumen-apposing metal stent (LAMS) and Self-expandable metal stent (SEMS) unique for gastric outlet obstruction?
The Lumen-apposing metal stent (LAMS) and Self-expandable metal stent (SEMS) are unique because they provide a minimally invasive option to relieve symptoms of gastric outlet obstruction, especially in patients who cannot undergo surgery. These stents expand within the body to open up blocked areas, offering effective palliation for those with inoperable conditions.1241011
Research Team
Mouen A Khashab, MD
Principal Investigator
Johns Hopkins University
Eligibility Criteria
Adults with malignant, unresectable gastric outlet obstruction and a GOOSS score of 0 or 1 can join. They must be able to undergo sedated endoscopy and fill out questionnaires. Excluded are those with severe clotting issues, complete obstruction, critical illness preventing endoscopy, bedridden status (WHO score of 4), resectable tumors, large ascites, pregnancy/breastfeeding, other GI strictures or prior related surgeries.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Lumen-apposing metal stent (Stent)
- Self-expandable metal stent (Stent)
Lumen-apposing metal stent is already approved in Canada, Japan for the following indications:
- Gastric outlet obstruction
- Biliary obstruction
- Gastric outlet obstruction
- Biliary obstruction
- Gastrointestinal fistula
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
Theodore DeWeese
Johns Hopkins University
Chief Executive Officer since 2023
MD from an unspecified institution
Allen Kachalia
Johns Hopkins University
Chief Medical Officer since 2023
MD from an unspecified institution
Boston Scientific Corporation
Industry Sponsor
Michael F. Mahoney
Boston Scientific Corporation
Chief Executive Officer since 2016
MBA from Wake Forest University, BBA in Finance from the University of Iowa
Kenneth Stein
Boston Scientific Corporation
Chief Medical Officer since 2020
MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology